In an attempt to further develop expertise, technology and manufacturing capabilities, Kerry Group has acquired two biotechnology companies. The latest move will see the Group merging with biotech firms in Mexico and Germany. The firms, c-LEcta in Germany and Enmex in Mexico will further develop new research within the Group.
According to Dr. Albert McQuaid, chief science and technology officer with Kerry, “the food and pharmaceutical industries are on the cusp of a new wave of innovation where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors.”
This was McQuaid’s take on the acquisition of c-LEcta. The newly acquired firm focuses on precision fermentation, bio-processing and bio-transformation to create ‘high-value targeted enzymes and ingredients.’ He adds that this will add new innovation capabilities in enzyme engineering and bio-process development.
Regarding the acquisition of Enmex, Kerry Group CEO of applied health and nutrition, Neil Cracknell says that the acquisition will complement the Group’s existing enzyme portfolio.
Enmex is a well-established enzyme manufacturer for the food, beverage and animal nutrition sectors. Cracknell comments that “enzymes play a critical role in helping achieve Kerry’s vision to create a world of sustainable nutrition, which is about providing better nutrition, with better processes, which have less impact on our earth’s resources.”
LSL News.